Home > Research > Publications & Outputs > Osteoarticular cells tolerate short-term exposu...

Electronic data

  • Author accepted manuscript NTBC and osteoarticular cells for pure

    Rights statement: The final publication is available at Springer via http://dx.doi.org/10.1007/s10067-015-2983-1

    Accepted author manuscript, 331 KB, PDF document

    Available under license: CC BY-NC: Creative Commons Attribution-NonCommercial 4.0 International License

Links

Text available via DOI:

View graph of relations

Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria

Research output: Contribution to journalJournal articlepeer-review

Published

Standard

Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. / Mistry, J. B.; Jackson, D. J.; Bukhari, Marwan; Taylor, Adam.

In: Clinical Rheumatology, Vol. 35, No. 2, 02.2016, p. 513-516.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Mistry, JB, Jackson, DJ, Bukhari, M & Taylor, A 2016, 'Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria', Clinical Rheumatology, vol. 35, no. 2, pp. 513-516. https://doi.org/10.1007/s10067-015-2983-1

APA

Mistry, J. B., Jackson, D. J., Bukhari, M., & Taylor, A. (2016). Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. Clinical Rheumatology, 35(2), 513-516. https://doi.org/10.1007/s10067-015-2983-1

Vancouver

Mistry JB, Jackson DJ, Bukhari M, Taylor A. Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. Clinical Rheumatology. 2016 Feb;35(2):513-516. https://doi.org/10.1007/s10067-015-2983-1

Author

Mistry, J. B. ; Jackson, D. J. ; Bukhari, Marwan ; Taylor, Adam. / Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria. In: Clinical Rheumatology. 2016 ; Vol. 35, No. 2. pp. 513-516.

Bibtex

@article{823d1cdf9cfe4410855d884f71ad1501,
title = "Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria",
abstract = "Alkaptonuria (AKU) is a rare genetic disease resulting in severe, rapidly progressing, early onset multi-joint osteoarthropathy. A potential therapy, nitisinone, is being trialled that reduces the causative agent; homogentisic acid (HGA) and in a murine model has shown to prevent ochronosis. Little is currently known about the effect nitisinone has on osteoarticular cells; these cells suffer most from the presence of HGA and its polymeric derivatives. This led us to investigate nitisinone{\textquoteright}s effect on chondrocytes and osteoblast-like cells in an in vitro model. Human C20/A4 immortalized chondrocytes, and osteosarcoma cells MG63 cultured in DMEM, as previously described. Confluent cells were then plated into 24-well plates at 4 × 104 cells per well in varying concentrations of nitisinone. Cells were cultured for 7 days with medium changes every third day. Trypan blue assay was used to determine viability and the effect of nitisinone concentration on cells. Statistical analysis was performed using analysis of variance, and differences between groups were determined by Newman-Keuls post-test. Analysis of C20/A4 chondrocyte and MG63 osteoblast-like cell viability when cultured in different concentrations of nitisinone demonstrates that there is no statistically significant difference in cell viability compared to control cultures. There is currently no literature surrounding the use of nitisinone in human in vitro models, or its effect on chondrocytes or osteoblast like cells. Our results show that nitisinone does not appear detrimental to cell viability of chondrocytes or osteoblast-like cells, which adds to the evidence that this therapy could be useful in treating AKU.",
keywords = "Alkaptonuria, Chondrocyte, Nitisinone, Ochronosis, Osteoblast ",
author = "Mistry, {J. B.} and Jackson, {D. J.} and Marwan Bukhari and Adam Taylor",
note = "The final publication is available at Springer via http://dx.doi.org/10.1007/s10067-015-2983-1",
year = "2016",
month = feb,
doi = "10.1007/s10067-015-2983-1",
language = "English",
volume = "35",
pages = "513--516",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "2",

}

RIS

TY - JOUR

T1 - Osteoarticular cells tolerate short-term exposure to nitisinone-implications in alkaptonuria

AU - Mistry, J. B.

AU - Jackson, D. J.

AU - Bukhari, Marwan

AU - Taylor, Adam

N1 - The final publication is available at Springer via http://dx.doi.org/10.1007/s10067-015-2983-1

PY - 2016/2

Y1 - 2016/2

N2 - Alkaptonuria (AKU) is a rare genetic disease resulting in severe, rapidly progressing, early onset multi-joint osteoarthropathy. A potential therapy, nitisinone, is being trialled that reduces the causative agent; homogentisic acid (HGA) and in a murine model has shown to prevent ochronosis. Little is currently known about the effect nitisinone has on osteoarticular cells; these cells suffer most from the presence of HGA and its polymeric derivatives. This led us to investigate nitisinone’s effect on chondrocytes and osteoblast-like cells in an in vitro model. Human C20/A4 immortalized chondrocytes, and osteosarcoma cells MG63 cultured in DMEM, as previously described. Confluent cells were then plated into 24-well plates at 4 × 104 cells per well in varying concentrations of nitisinone. Cells were cultured for 7 days with medium changes every third day. Trypan blue assay was used to determine viability and the effect of nitisinone concentration on cells. Statistical analysis was performed using analysis of variance, and differences between groups were determined by Newman-Keuls post-test. Analysis of C20/A4 chondrocyte and MG63 osteoblast-like cell viability when cultured in different concentrations of nitisinone demonstrates that there is no statistically significant difference in cell viability compared to control cultures. There is currently no literature surrounding the use of nitisinone in human in vitro models, or its effect on chondrocytes or osteoblast like cells. Our results show that nitisinone does not appear detrimental to cell viability of chondrocytes or osteoblast-like cells, which adds to the evidence that this therapy could be useful in treating AKU.

AB - Alkaptonuria (AKU) is a rare genetic disease resulting in severe, rapidly progressing, early onset multi-joint osteoarthropathy. A potential therapy, nitisinone, is being trialled that reduces the causative agent; homogentisic acid (HGA) and in a murine model has shown to prevent ochronosis. Little is currently known about the effect nitisinone has on osteoarticular cells; these cells suffer most from the presence of HGA and its polymeric derivatives. This led us to investigate nitisinone’s effect on chondrocytes and osteoblast-like cells in an in vitro model. Human C20/A4 immortalized chondrocytes, and osteosarcoma cells MG63 cultured in DMEM, as previously described. Confluent cells were then plated into 24-well plates at 4 × 104 cells per well in varying concentrations of nitisinone. Cells were cultured for 7 days with medium changes every third day. Trypan blue assay was used to determine viability and the effect of nitisinone concentration on cells. Statistical analysis was performed using analysis of variance, and differences between groups were determined by Newman-Keuls post-test. Analysis of C20/A4 chondrocyte and MG63 osteoblast-like cell viability when cultured in different concentrations of nitisinone demonstrates that there is no statistically significant difference in cell viability compared to control cultures. There is currently no literature surrounding the use of nitisinone in human in vitro models, or its effect on chondrocytes or osteoblast like cells. Our results show that nitisinone does not appear detrimental to cell viability of chondrocytes or osteoblast-like cells, which adds to the evidence that this therapy could be useful in treating AKU.

KW - Alkaptonuria

KW - Chondrocyte

KW - Nitisinone

KW - Ochronosis

KW - Osteoblast

U2 - 10.1007/s10067-015-2983-1

DO - 10.1007/s10067-015-2983-1

M3 - Journal article

VL - 35

SP - 513

EP - 516

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 2

ER -